一种铑（III）配合物作为针对TP53突变三阴性乳腺癌细胞的Wee1抑制剂的鉴定。
Identification of a rhodium(iii) complex as a Wee1 inhibitor against TP53-mutated triple-negative breast cancer cells.
作者信息
Yang Guan-Jun, Zhong Hai-Jing, Ko Chung-Nga, Wong Suk-Yu, Vellaisamy Kasipandi, Ye Min, Ma Dik-Lung, Leung Chung-Hang
机构信息
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
出版信息
Chem Commun (Camb). 2018 Mar 6;54(20):2463-2466. doi: 10.1039/c7cc09384e.
The rhodium(iii) complex 1 was identified as a potent Wee1 inhibitor in vitro and in cellulo. It decreased Wee1 activity and unscheduled mitotic entry, and induced cell damage and death in TP53-mutated triple-negative breast cancer cells. 1 represents a promising scaffold for further development of more potent metal-based Wee1 antagonists.
铑（III）配合物1在体外和细胞内被鉴定为一种有效的Wee1抑制剂。它降低了Wee1活性和非计划有丝分裂进入，并在TP53突变的三阴性乳腺癌细胞中诱导细胞损伤和死亡。1代表了一个有前景的骨架，可用于进一步开发更有效的金属基Wee1拮抗剂。
Zotero 插件